Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED

Inclusion Criteria: * Patient Informed consent form (ICF) signed. * Males and Females aged ≥18 years at the time of the signature of ICF. * Patients with moderate dry eye disease (DED) according to IDEEL questionnaire (score ≥51 and ≤64) and diagnosed at least 3 months before enrolment. * No use of other tear substitutes in the 5 days prior to enrolment, except for refresh solutions. * TBUT value \<6 sec. * Willing to follow all study procedures, including attending all site visits, tests and examinations. * Women must agree to be using two forms of effective contraception, be post-menopausal from at least 12 months prior to trial entry, or surgically sterile. Exclusion Criteria: * Patients with a mild or severe dry eye disease (DED) according to IDEEL questionnaire (score ≤50 and ≥65, respectively). * Use of ophthalmologic products in the 14 days prior to enrolment, except for refresh solutions and stable glaucoma treatment. * No previous history or presence of any disease involving cornea or conjunctiva. * Sjӧgren syndrome. * History or active cicatricial conjunctivitis. * History of ocular surface burns. * Use of contact lenses. * Corneal refractive surgery 1 year post-operative. * Any ocular surgery in the previous 3 months preceding the study. * Unstable glaucoma (treatment changes in the last year). * Any macular or retinal disease that could impact visual acuity. * Best corrected visual acuity (BCVA) below 20/40. * Blepharitis treatment started less than 3 months before enrolment. * Neurological, neurodegenerative or cerebrovascular conditions. * Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular, cancer or hematological disease. * Unstable treatment with systemic medications, such as diuretics, antihistamines, antidepressants, psychotropics, cholesterol lowering agents and beta-blockers. * Known hypersensitivity to one of the administered products. * Known drug and/or alcohol abuse. * Mental incapacity that precludes adequate understanding or cooperation. * Participation in another investigational study or blood donation within 1 month prior to ICF signature.